688321 Shenzhen Chipscreen Biosciences
- 18.03
- +0.05+0.28%
Shenzhen Chipscreen Biosciences News
Guotou Securities Co., Ltd.'s verification opinion regarding the use of temporarily idle raised funds by Shenzhen Chipscreen Biosciences Co., Ltd. for cash management.
Announcement regarding the use of temporarily idle raised funds for cash management.
Voluntary disclosure announcement regarding the approval of clinical trial notification for the treatment of colorectal cancer with Xidabenamine.
Voluntary disclosure of the announcement regarding the approval of the indications for the use of empagliflozin and metformin hydrochloride in the treatment of type 2 diabetes.
Announcement on the results of convertible bonds and changes in shareholding
Announcement regarding the interest payment for Weichip Convertible Bonds in 2024.
CSI Securities Co., Ltd.'s entrusted management report on Shenzhen Chipscreen Biosciences Co., Ltd.'s issuance of convertible corporate bonds to unspecified objects (2023). Bonds.
Announcement about not adjusting the conversion price of "Wichips Convertible Bonds" downward.
In 2022, Shenzhen Chipscreen Biosciences Co., Ltd. issued convertible corporate bonds to unspecified investors. The tracking rating report is for 2024.
Announcement regarding the credit rating results of the Weichip Convertible Bond Tracking.
Voluntary disclosure on the Notice of Approval for Clinical Trials of Xeloda Capsules for the treatment of pancreatic cancer.
Announcement for the Expected Fulfillment of Conversion Price Adjustment Conditions regarding 'Microchip Convertible Bonds'.
Investor Relations Activity Record Table, June 4, 2024.
Voluntary disclosure of announcements regarding the company's drugs to be included in breakthrough therapeutic categories
Announcement on the adjustment of the conversion price of the convertible corporate bond “Microchip Convertible Bonds” and the suspension and resumption of trading
Announcement on the implementation of share repurchase cancellation and share changes
Notice on Response to the 2023 Annual Report Information Disclosure Regulatory Inquiry Letter
China Investment Securities Co., Ltd.'s inspection opinion on the response to the information disclosure regulatory inquiry letter on the 2023 annual report of Shenzhen Microchip Biotechnology Co., Ltd.
KPMG Huazhen Certified Public Accountants (Special General Partnership) Special Response Instructions to the Information Disclosure Regulatory Inquiry Letter on the 2023 Annual Report of Shenzhen Microchip Biotechnology Co., Ltd.
Investor Relations Activity Record Form 2024/5/15
Analysis
Price Target
No Data
